Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Paul Gleeson

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
Bioorganic & Medicinal Chemistry|January 10, 2026
Computationally guided design of N<sup>4</sup>-(2-methyl-2H-indazol-6-yl)-N<sup>2</sup>-phenylpyrimidine-2,4-diamine inhibitors of EGFR kinase targeting Cys797Adchata Konsue, Duangkamol Gleeson, Kiattawee Choowongkomon, et al.
Current Pharmaceutical Design|February 10, 2012
The challenges involved in modeling toxicity data in silico: a reviewM Paul Gleeson, Sandeep Modi, Andreas Bender, et al.
RSC Medicinal Chemistry|December 23, 2022
Preparation, biological evaluation and QSAR analysis of urea substituted 2,4-diamino-pyrimidine anti-malarialsBorvornwat Toviwek, Jennifer Riley, Nicole Mutter, et al.
Bioorganic & Medicinal Chemistry|September 19, 2024
Design, preparation and biological evaluation of new Rociletinib-inspired analogs as irreversible EGFR inhibitors to treat non-small-cell-lung cancerAdchata Konsue, Thomanai Lamtha, Duangkamol Gleeson, et al.
Vascular Pharmacology|September 26, 2022
Quinazoline-based human phosphodiesterase 5 inhibitors exhibited a selective vasorelaxant effect on rat isolated pulmonary arteries involving NO-sGC-cGMP pathway and calcium inhibitory effectsUsana Chatturong, Hélène Martin, Perle Totoson, et al.
Bioorganic & Medicinal Chemistry|November 30, 2022
Computational design, synthesis and biological evaluation of PDE5 inhibitors based on N<sup>2</sup>,N<sup>4</sup>-diaminoquinazoline and N<sup>2</sup>,N<sup>6</sup>-diaminopurine scaffoldsThanachon Somnarin, Nattakarn Pobsuk, Ruttanaporn Chantakul, et al.
Bioorganic & Medicinal Chemistry|September 3, 2021
Preparation, biological & cheminformatics-based assessment of N<sup>2</sup>,N<sup>4</sup>-diphenylpyrimidine-2,4-diamine as potential Kinase-targeted antimalarialsBorvornwat Toviwek, Oraphan Phuangsawai, Adchatawut Konsue, et al.
Bioorganic & Medicinal Chemistry Letters|December 5, 2018
Design, synthesis and evaluation of N<sup>2</sup>,N<sup>4</sup>-diaminoquinazoline based inhibitors of phosphodiesterase type 5Nattakarn Pobsuk, Tamkeen Urooj Paracha, Nattiya Chaichamnong, et al.
Journal of Computer-Aided Molecular Design|November 24, 2007
Generation of in-silico cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A4 inhibition QSAR modelsM Paul Gleeson, Andrew M Davis, Kamaldeep K Chohan, et al.
Molecules (Basel, Switzerland)|January 17, 2019
Elucidation of Vasodilation Response and Structure Activity Relationships of <i>N</i>²,<i>N</i>⁴<i>-</i>Disubstituted Quinazoline 2,4-Diamines in a Rat Pulmonary Artery ModelTamkeen Urooj Paracha, Nattakarn Pobsuk, Nattapas Salaloy, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
Bioorganic & Medicinal Chemistry|January 10, 2026
Computationally guided design of N<sup>4</sup>-(2-methyl-2H-indazol-6-yl)-N<sup>2</sup>-phenylpyrimidine-2,4-diamine inhibitors of EGFR kinase targeting Cys797Adchata Konsue, Duangkamol Gleeson, Kiattawee Choowongkomon, et al.
Current Pharmaceutical Design|February 10, 2012
The challenges involved in modeling toxicity data in silico: a reviewM Paul Gleeson, Sandeep Modi, Andreas Bender, et al.
RSC Medicinal Chemistry|December 23, 2022
Preparation, biological evaluation and QSAR analysis of urea substituted 2,4-diamino-pyrimidine anti-malarialsBorvornwat Toviwek, Jennifer Riley, Nicole Mutter, et al.
Bioorganic & Medicinal Chemistry|September 19, 2024
Design, preparation and biological evaluation of new Rociletinib-inspired analogs as irreversible EGFR inhibitors to treat non-small-cell-lung cancerAdchata Konsue, Thomanai Lamtha, Duangkamol Gleeson, et al.
Vascular Pharmacology|September 26, 2022
Quinazoline-based human phosphodiesterase 5 inhibitors exhibited a selective vasorelaxant effect on rat isolated pulmonary arteries involving NO-sGC-cGMP pathway and calcium inhibitory effectsUsana Chatturong, Hélène Martin, Perle Totoson, et al.
Bioorganic & Medicinal Chemistry|November 30, 2022
Computational design, synthesis and biological evaluation of PDE5 inhibitors based on N<sup>2</sup>,N<sup>4</sup>-diaminoquinazoline and N<sup>2</sup>,N<sup>6</sup>-diaminopurine scaffoldsThanachon Somnarin, Nattakarn Pobsuk, Ruttanaporn Chantakul, et al.
Bioorganic & Medicinal Chemistry|September 3, 2021
Preparation, biological & cheminformatics-based assessment of N<sup>2</sup>,N<sup>4</sup>-diphenylpyrimidine-2,4-diamine as potential Kinase-targeted antimalarialsBorvornwat Toviwek, Oraphan Phuangsawai, Adchatawut Konsue, et al.
Bioorganic & Medicinal Chemistry Letters|December 5, 2018
Design, synthesis and evaluation of N<sup>2</sup>,N<sup>4</sup>-diaminoquinazoline based inhibitors of phosphodiesterase type 5Nattakarn Pobsuk, Tamkeen Urooj Paracha, Nattiya Chaichamnong, et al.
Journal of Computer-Aided Molecular Design|November 24, 2007
Generation of in-silico cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A4 inhibition QSAR modelsM Paul Gleeson, Andrew M Davis, Kamaldeep K Chohan, et al.
Molecules (Basel, Switzerland)|January 17, 2019
Elucidation of Vasodilation Response and Structure Activity Relationships of <i>N</i>²,<i>N</i>⁴<i>-</i>Disubstituted Quinazoline 2,4-Diamines in a Rat Pulmonary Artery ModelTamkeen Urooj Paracha, Nattakarn Pobsuk, Nattapas Salaloy, et al.
Pageof 6